Summit Therapeutics Share Discussion Threads

[waterloo01] 11/4/2018 14:10

So much hangs on the 48wk data but the FDA paper recently does back up the MRI endpoint and good to hear Roblin reference it. If they get accelerated approval (some months after the results) then SRPT milestone kicks in.

[chrisatrdg] 11/4/2018 14:08

Todays call sounded positive but there is always the issue of future funding beyond April 2019 however if the second part of the DMD trials is as good as the first 24 wks there should be a significant appreciation in the share price latter this year.C-Diff now moves into next year.

So far the share price today has not moved so wait & see what happens on the NASDAQ.

In summary a good day for Summit & clearly much interest based on the many phone calls I think the most that I can remember.

Look forward to other peoples views on the science front.

[waterloo01] 11/4/2018 12:38

Conference call details

please dial [phone] (UK and international participants) or [phone]
(US local number) and use the conference confirmation code 1980085.

[waterloo01] 11/4/2018 12:09

Might we hear in the call about other rights ex US?

[hugus maximus] 11/4/2018 12:07

Y/E RNS I would imagine analysts will like this ... losses a lot less than previous year and the sums look good for SUMM ... suspect these will be well received. Write up for Ezutromid accelerated approval looking very purposeful. EXCELLENT.

[waterloo01] 11/4/2018 12:06

The 24-week data have bolstered our confidence that ezutromid could become the standard of care for all patients with DMD. We are preparing ourselves to rapidly advance ezutromid towards the market after receipt of the 48-week data. We see two potential paths to get to market with positive 48-week data. In one scenario, we could potentially pursue accelerated approval in the US based on the 48-week data. In another scenario, we conduct a pivotal, placebo controlled trial that would be the basis of regulatory filings for approvals in the US and EU. Our recent fundraise in Europe allows us to maintain clinical and regulatory flexibility for both of these options. We remain committed to independently commercialising ezutromid in the United States, one the world's most important pharmaceutical markets, while our partner, Sarepta Therapeutics, has commercialisation rights in Europe.

[hugus maximus] 11/4/2018 08:35

It would be helpful if the books being published aren't bad (and which should at least show some cash sitting in the account) ... thus simply encouraging positive attention from analysts to what's anticipated with DMD 48 wk results.

Whilst most investors won't possibly grasp the detail of DMD research (Exon skipping versus Utrophin modulation ... 6MWT versus biomarker end points etc)... one would hope that analysts will start to do their stuff over the coming weeks and push up the share price with some positive opinion.

[waterloo01] 10/4/2018 19:01

The more I see the 24wk results the more I like them. Also the reminder that SRPT will have to cover 45% of costs going forward on the phase 3 or confirmatory study.

'This data opens up the possibility of an accelerated path to market'

Also seems fairly confident that will get Wellcome/Barda type funding for Gonorrhoea.

Interesting to hear that Some years ago two fund managers almost lost their jobs for thinking of backing antibiotics! Some things got to give at some point re value of antibiotics, but despite the scary resistance and big words from Government, money still isn't flowing.

[algernon2] 10/4/2018 18:30

Just listened to the webcast: Nice to know Glyn is "super-excited" about some of the Dmd data and not just "excited".
Re the clapping at the end it sounded like only about 5 people were actually there.
I trust there were more than this number and they just generally don't clap like they would after a concert or opera..
Anyone any idea how many were left standing there for this penultimate presentation of the day?
Some interesting facts on Gonorrhea re the last working usable Anti-biotic (combo) and the high level of resistance to it in Japan.May attract a lot of money in the next few years (my opinion there).
All in all very comforting.

[football] 10/4/2018 15:34

What would be a good set of results for summit plc tomorrow or is it all about the forward-looking statement and what they have in the pipeline?

[chrisatrdg] 10/4/2018 15:05

Hi waterloo01 Not sure link below:

[waterloo01] 10/4/2018 14:48

I missed the call. Did he mention about the use of MRI and alternative endpoints?

[chrisatrdg] 10/4/2018 14:40

Todays conference call had Glyn sounding very excited about progress today on DMD & hopefully Summit will achieve accelerated progress with approval with the FDA in the US.

The other 2 shots on goal sounded interesting but clearly Phase 3 for C-Diff will require a heavy lift partially supported by US Government but there is still a shortfall.

Discuva is early days but the Gonorrhea will move forward in H2 2018.

The game changer this year is 48 Wk results Qtr 3 2018 as we all know.

It is just a matter of waiting & seeing potential is clearly a multi bagger

[hugus maximus] 10/4/2018 11:31

Thanks Football ... let's move forward with the sweet thought that someone, somewhere values this share at $145 and leave the rest to the ant that moved the rubber tree plant! (Quote from my mantra "High Hopes" -Frank Sinatra)

[football] 10/4/2018 10:39

Also my two buys today ones gone through as a sell and the other hasn't shown up yet?

[football] 10/4/2018 10:28

When you search Google for the text below

<"$SMMT fp - 1. Summit Therapeutics Shares Move Higher as Traders Circulated Report of Buy Recommendation, $147 Price Target at Agora 12:07 pm ET April 9, 2018 (Benzinga) Latest Ratings for SMMT DateFirmActionFromTo Feb 2018BTIG ResearchInitiates Coverage">


It shows this webpage but for the life of me I can't see it anywhere even though Google results says it's there, I should of went to SpecSavers

[hugus maximus] 10/4/2018 10:07

Bizarre .. be interesting to find the source article ... I just subscribed to Agora and still can't find the source?

[waterloo01] 10/4/2018 10:01

Also can't find reference to it but Agora isn't a one man band, I've known about them for about 10 years (was in similar business years back) and have some decent writers. Didn't know they also did share research!

[hugus maximus] 10/4/2018 09:53

Morning chaps ... it was a note that someone put up on Share Gumtree and routes back to "Agora Financial UK"?? I can't find a URL for the actual source but this is the extract on Share Gumtree:

<"$SMMT fp - 1. Summit Therapeutics Shares Move Higher as Traders Circulated Report of Buy Recommendation, $147 Price Target at Agora 12:07 pm ET April 9, 2018 (Benzinga) Latest Ratings for SMMT DateFirmActionFromTo Feb 2018BTIG ResearchInitiates Coverage">

I get the impression that Agora is just some one man band. "$147" nice but based on what?

[waterloo01] 09/4/2018 18:33

No I also looked but just mention by someone on Twitter. $smmt

[football] 09/4/2018 18:15

waterloo01 do have have a link to the tip has i can find it


tia




NASDAQ: up 12%

[waterloo01] 09/4/2018 17:33

Tipped by Agora (?) according to twitter with a $147 target!

[hugus maximus] 09/4/2018 17:23

Someone just bought a brace of shares in the states taking the share price to $13.75. This does all feel as if at any moment we might see Rex Harrison appear in 'My Fair Lady' and break into "she's got it ... by George she's got it"!

Having seen the Sarapeta scenario unfold, I simply can't imagine we have to go as far as 48 wk results (given the pointers in biomarkers present in 24 wk results) until some threshold effect brings in more folk who like the real potential of a little mark cap company like Summit with such a solid looking drug.

There's a conference call on Wednesday with the end of year figures and perhaps some more detail on the data for 24 wk results?

FDA certainly looking to favour some serious alternative objective "end points" and a drug like Ezutromid is ticking their boxes in the way it's been tested.

GLA

[chrisatrdg] 09/4/2018 15:10

RNS out re Notice of results for this Wednesday:

[chrisatrdg] 09/4/2018 12:08

Registration now open for HC Wainwright Healthcare Conference 2.00 UK time this Tuesday: